阿维莫泮在开放与微创结直肠手术中均与良好结局相关:区域数据库分析
该回顾性队列分析纳入密歇根外科质量协作区域风险调整数据库2018至2021年结直肠手术患者10010例,其中4919例围术期使用阿维莫泮、5091例未使用。校正后阿维莫泮与住院时间缩短9.6%、肠功能恢复时间缩短14.9%、术后肠梗阻减少42.1%相关,且微创手术亚组中三项结局均显著获益。
要点
- 围术期阿维莫泮与结直肠手术住院时间、肠功能恢复时间缩短及术后肠梗阻减少相关。
- 获益不限于开放手术,腹腔镜与机器人微创结直肠手术亚组同样显著。
- 研究为回顾性区域数据库分析,需前瞻性验证以确立因果关系。
核心结论
- 围术期阿维莫泮与结直肠手术患者住院时间缩短、肠功能恢复时间缩短及术后肠梗阻减少相关。
- 该获益不限于开放手术,也见于微创腹腔镜与机器人结直肠手术。
研究设计与样本
- 回顾性队列分析,数据来自密歇根外科质量协作区域风险调整数据库2018至2021年。
- 共纳入10010例结直肠手术患者,4919例围术期使用阿维莫泮,5091例未使用。
- 手术方式构成:开放30.3%、腹腔镜40.5%、手助腹腔镜12.7%、机器人43.5%。
主要发现
- 未校正分析:阿维莫泮组术后住院时间4.75天 vs 5.5天(p < 0.001)。
- 未校正分析:阿维莫泮组肠功能恢复时间1.61天 vs 2.01天(p < 0.001)。
- 未校正分析:阿维莫泮组术后肠梗阻发生率5.45% vs 7.94%(p < 0.001)。
- 校正后回归模型:阿维莫泮与住院时间减少9.6%(p < 0.001)、肠功能恢复时间缩短14.9%(p < 0.001)、术后肠梗阻减少42.1%(p < 0.001)相关。
- 亚组分析显示微创手术患者三项结局均显著获益。
临床怎么用
- 对于结直肠手术患者,可考虑围术期使用阿维莫泮以促进肠功能恢复、缩短住院并降低术后肠梗阻。
- 微创结直肠手术患者同样可能从阿维莫泮中获益,不应仅局限于开放手术。
局限性
- 研究为回顾性队列分析,存在未测量混杂因素的可能。
- 数据来源于单一区域数据库,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alvimopan is a µ-opioid receptor antagonist associated with shorter time to gastrointestinal recovery in patients having open colorectal surgery. Data demonstrating the benefit of perioperative alvimopan for the minimally invasive surgical approach are inconsistent. The aim of this study is to determine colorectal surgery groups that benefit from perioperative alvimopan. METHODS: This is a retrospective cohort analysis of colorectal surgery patients who had, and patients who did not have, perioperative alvimopan in the Michigan Surgical Quality Collaborative regional risk-adjusted database from 2018 through 2021. Main outcome measures were postoperative length of hospital stay, time to return of bowel function, and postoperative ileus. RESULTS: There were 10,010 patients (30.3% open, 40.5% laparoscopic, 12.7% hand-assist laparoscopic, 43.5% robotic) who met inclusion criteria-4919 received alvimopan in the perioperative period and 5091 did not. When compared to those not receiving alvimopan, unadjusted outcomes showed that the alvimopan group had significantly shorter postoperative length of stay (4.75 days vs 5.5 days, p < 0.001), shorter time to return of bowel function (1.61 days vs 2.01 days, p < 0.001) and less postoperative ileus (5.45% vs 7.94%, p < 0.001). After adjustment, regression models confirmed that alvimopan was associated with an 9.6% reduction in hospital length of stay (p < 0.001), a 14.9% shorter time to return of bowel function (p < 0.001), and a 42.1% reduction in postoperative ileus (p < 0.001). Subgroup analysis showed significant benefit of alvimopan for all three outcomes in patients having the minimally invasive approach. CONCLUSIONS: Alvimopan is associated with shorter hospital length of stay, shorter time to return of bowel function, and decreased postoperative ileus when administered to patients undergoing colorectal surgery. Benefit is not limited to the open approach and includes minimally invasive laparoscopic and robotic colorectal procedures.
引用
- Kaarto P, Westfall KM, Brockhaus K, et al. Alvimopan is associated with favorable outcomes in open and minimally invasive colorectal surgery: a regional database analysis. Surg Endosc. 2023. PMID: 37130983. doi:10.1007/s00464-023-10098-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。